#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Warm autoimmune haemolytic anaemia Acquired C1 inhibitor deficiency Chemical burn Glomerulonephritis rapidly progressive Undifferentiated sarcoma Antithrombin III deficiency Plasma cell myeloma Bulbospinal muscular atrophy congenital Selective polysaccharide antibody deficiency Myotonia Chronic graft versus host disease Waldenstrom's macroglobulinaemia Congenital ectodermal dysplasia Breast angiosarcoma metastatic Aspergillus infection More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis I – Treatment Metachromatic leukodystrophy – Treatment Mast cell activation syndrome – Life with Disease Bronchiolitis obliterans syndrome Arterial tortuosity syndrome – Diagnostics Undifferentiated sarcoma – Diagnostics Hereditary hypophosphataemic rickets – Life with Disease Andersen-Tawil syndrome – Treatment Systemic mastocytosis – Treatment SAPHO syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Abc-23B-116 Rosnilimab Paeonol Seladelpar Crofelemer Goserelin Rimegepant Iph5201 Methotrexate Sodium ULVIPRUBART AUR200 H2-Receptor Antagonists Eprosartan Mesilate LTI-03 Ttf-Ngr ARLOCABTAGENE AUTOLEUCEL Farletuzumab Ecteribulin Fluvastatin Sodium Human Fibrinogen Piritramide More therapies…

    Learn about Your Condition

    Dizziness Vitiligo Metastases to meninges Acute promyelocytic leukaemia Thrombosis prophylaxis Lennox-Gastaut syndrome Anxiety disorder Tympanic membrane hyperaemia Cholestatic pruritus Glioma Triple positive breast cancer Femoral hernia Myotonia Oesophagectomy Lung transplant rejection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Phase 3 Study of INCB123667 versus investigator’s choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Topotecan Hydrochloride
    • INCB123667
    • Doxorubicin Hydrochloride
    Belgium France Germany Ireland Italy The Netherlands +2

  • A Phase 3 Study of Fenfluramine Hydrochloride for Safety and Efficacy in Patients with Rett Syndrome

    Recruiting

    3 1 1
    Investigated Drugs:
    • Fenfluramine Hydrochloride
    Belgium France Germany Hungary Italy Poland +1

  • Phase 1/2 Study of LB-208 in Adults with Relapsed or Refractory Acute Myeloid Leukaemia and High‑Risk Myelodysplastic Syndrome

    Recruiting

    1 1 1
    Spain

  • Long‑Term Safety and Efficacy of Infigratinib in Children with Hypochondroplasia

    Recruiting

    2 1 1
    Investigated Drugs:
    • Infigratinib
    Norway Spain

  • Glofitamab plus drug combination for relapsed/refractory large B‑cell lymphoma in high‑risk second‑line patients eligible for CAR‑T therapy

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Glofitamab
    • Axicabtagene Ciloleucel
    • Obinutuzumab
    Germany

  • Phase II Study of Intravenous Tarlatamab for Patients with Asymptomatic Brain Metastases from Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Drugs:
    • Tarlatamab
    The Netherlands
Previous Page
1 … 29 30 31 32 33 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!